Trial Profile
Phase II study of biweekly cetuximab and irinotecan as third-line therapy in patients with pre-treated KRAS exon2 wild-type metastatic colorectal cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Oct 2016
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Irinotecan (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 21 Oct 2016 New trial record